Stayble Therapeutics publishes half-year report for 2023
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its half-year report for 2023. The report is available as an attached document and on the Company's website, www.staybletherapeutics.com/en/investors/financial-reports/. Below is a summary of the report.Summary Highlights during the second quarter (April – June 2023) · In April, positive interim data from the ongoing phase 2b study were presented, confirming safety and tolerability, as well as lower deviation in pain measurements compared to initial assumptions when analyzing blinded data from the six-month